Румунія - румунська - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

bayer pharma ag - ciprofloxacinum - compr. film. elib. prel. - 500 mg - chinolone antibacteriene fluorochinolone

Молдова - румунська - ANSA (Agenţia Naţională pentru Siguranţa Alimentelor)

reefco, iordania - vit.c, - pulbere - păsări

Молдова - румунська - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

kesar pharma pvt. ltd - ciprofloxacinum + tinidazolum - comprimate filmate - 500 mg + 600 mg

Румунія - румунська - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

bayer pharma ag - germania - ciprofloxacinum - compr. film. elib. prel. - 1000 mg - chinolone antibacteriene fluorochinolone

Румунія - румунська - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

bayer pharma ag - germania - ciprofloxacinum - compr. film. elib. prel. - 500 mg - chinolone antibacteriene fluorochinolone

Європейський Союз - румунська - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - agenți antineoplazici - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq cum este indicat în monoterapie pentru tratamentul pacienților adulți cu nsclc local avansat sau metastatic după chimioterapie anterioară. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq cum este indicat în monoterapie pentru tratamentul pacienților adulți cu nsclc local avansat sau metastatic după chimioterapie anterioară. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Румунія - румунська - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

rotexmedica gmbh - germania - oxytocinum - sol inj./perf. - 5ui/ml - hormoni ai lobului posterior hipofizar oxitocina si analogi

Європейський Союз - румунська - EMA (European Medicines Agency)

qbiotics netherlands b.v. - tigilanol tiglate - tigilanol tiglate - câini - pentru tratamentul non-rezecabile, non-metastatic (care de intermediere) subcutanat de celule catarg tumori localizate la nivelul sau distal de cot sau genunchi, și non-rezecabile, non metastaze cutanate tumorile mastocitare în câini.

Молдова - румунська - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

nobel ilac sanayii ve ticaret a.Ş. - ciprofloxacinum - comprimate filmate - 500 mg

Європейський Союз - румунська - EMA (European Medicines Agency)

astellas pharma europe b.v. - enfortumab vedotin - carcinoma, transitional cell; urologic neoplasms - agenți antineoplazici - padcev as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial cancer who have previously received a platinum-containing chemotherapy and a programmed death receptor 1 or programmed death ligand 1 inhibitor.